Pharmacological treatment of obesity is associated with post-cessation weight regain or weight cycling a further concern in the context of sarcopenia
Treatment for hepatorenal syndrome, if this is present
A randomized, placebo-controlled trial published in Diabetes, Obesity and Metabolism found that semaglutide led to a 24% reduction in total daily energy intake compared to placebo, driven primarily by reduced appetite and fewer food cravings rather than nausea or food aversion
Sci Rep 6:26859 Acknowledgements This work was funded by Action Medical Research (GN2485)
Follow the prescribed dosing schedule, maintaining a consistent weekly injection day
HRT with bioidentical pellets hormone replacement for women and men using the EvexiPEL method, with the pellet placed just under the skin and re-inserted every three to four months